Material Safety Data Sheet

Vinpocetine

sc-201204

Hazard Alert Code Key:

EXTREME  HIGH  MODERATE  LOW

Section 1 - CHEMICAL PRODUCT AND COMPANY IDENTIFICATION

PRODUCT NAME
Vinpocetine

STATEMENT OF HAZARDOUS NATURE

NFPA

SUPPLIER
Santa Cruz Biotechnology, Inc.
2145 Delaware Avenue
Santa Cruz, California 95060
800.457.3801 or 831.457.3800

EMERGENCY:
ChemWatch
Within the US & Canada: 877-715-9305
Outside the US & Canada: +800 2436 2255
(1-800-CHEMCALL) or call +613 9573 3112

SYNONYMS
C22-H26-N2-O2, "ethyl apovincaminate", "(3alpha, 16alpha)-eburnamenine-14-carboxylic acid ethyl ester", "eburnamenine-14-carboxylic acid ethyl ester", "3alpha, 16alpha-apovincaminic acid ethyl ester", "ethyl apovincamin-22-oate", Cavinton, Intelectol, "vasodilator (cerebral)"

Section 2 - HAZARDS IDENTIFICATION

CHEMWATCH HAZARD RATINGS

<table>
<thead>
<tr>
<th></th>
<th>Min</th>
<th>Max</th>
</tr>
</thead>
<tbody>
<tr>
<td>Flammability</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>Toxicity</td>
<td>2</td>
<td></td>
</tr>
<tr>
<td>Body Contact</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>Reactivity</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>Chronic</td>
<td>2</td>
<td></td>
</tr>
</tbody>
</table>

CANADIAN WHMIS SYMBOLS
EMERGENCY OVERVIEW

RISK
Harmful if swallowed.
Harmful: danger of serious damage to health by prolonged exposure through inhalation.

POTENTIAL HEALTH EFFECTS

ACUTE HEALTH EFFECTS

SWALLOWED
- Accidental ingestion of the material may be harmful; animal experiments indicate that ingestion of less than 150 gram may be fatal or may produce serious damage to the health of the individual.
- The main features defining a nootropic drugs (cognitive enhancers) are:
  - the enhancement of learning and memory acquisition
  - protection of the brain against various physical or chemical injury
  - facilitation of flow of information between the hemispheres of the brain
  - absence of usual negative effects of psychotropic drugs particularly central nervous system toxicity.
- Extensive study of the modes of action of the nootropics reveals certain pharmacological effects. There appears to be no single predominant mode of action shared by the whole class of drugs, however all influence cholinergic function. By increasing high affinity choline uptake these drugs facilitate acetylcholine production and turnover with various actions at both muscarinic and nicotinic receptors (there is a serious decline in acetylcholine reception in aged humans).
- Occasional side-effects may include nausea, vomiting, headache, blurred vision, skin rashes, nasal stuffiness, flushing of the skin, dizziness, bradycardia and orthostatic hypotension. Cardiovascular effects may include sinus bradycardia.
- When given by mouth or by injection, in therapeutic doses, vasodilators may produce transient flushing of the face, a sensation of heat, a pounding in the head, peripheral oedema, headache, hypotension, palpitations, dizziness and fatigue. Most reactions are dose dependent and transient. High doses may cause flushing and dryness of the skin, skin lesions, abdominal cramps, diarrhoea, nausea, vomiting, malaise, anorexia, activation of peptic ulcer, jaundice and impairment of liver function, decrease in glucose tolerance, mild diabetes and hyperuricaemia. Most of these effects subside with withdrawal of the drug.

EYE
- Although the material is not thought to be an irritant, direct contact with the eye may cause transient discomfort characterized by tearing or conjunctival redness (as with windburn). Slight abrasive damage may also result.

SKIN
- Skin contact is not thought to produce harmful health effects (as classified using animal models). Systemic harm, however, has been identified following exposure of animals by at least one other route and the material may still produce health damage following entry through wounds, lesions or abrasions.
- Open cuts, abraded or irritated skin should not be exposed to this material.
- Entry into the blood-stream, through, for example, cuts, abrasions or lesions, may produce systemic injury with harmful effects. Examine the skin prior to the use of the material and ensure that any external damage is suitably protected.

INHALED
- The material is not thought to produce respiratory irritation (as classified using animal models). Nevertheless inhalation of dusts, or fume, especially for prolonged periods, may produce respiratory discomfort and occasionally, distress.
- Inhalation of dusts, generated by the material during the course of normal handling, may be damaging to the health of the individual.
- Persons with impaired respiratory function, airway diseases and conditions such as emphysema or chronic bronchitis, may incur further disability if excessive concentrations of particulate are inhaled.
- Side effects of topoisoamerase I and II inhibitors (acting as antineoplastics/ cytotoxics) include early diarrhoea which may occur within 24 hours of exposure to the drug; this may be accompanied by symptoms including runny nose, increased salivation, watery eyes, sweating, flushing, abdominal cramping. Late diarrhoea may occur after 24 hours and usually peaks at about 11 days after treatment. Because of concerns of dehydration and electrolyte imbalances with diarrhoea it is important to be in contact with health care professionals for monitoring, and for medication and diet modifications advice.
- Other common side-effects of therapy may include nausea and vomiting may also occur; low red and white blood cell counts may also result; anaemia may follow. Hair loss, poor appetite, fever and weight loss may also ensue. Less common symptoms include constipation, shortness of breath, insomnia, cough, headache, dehydration, chills, skin rash, flatulence, flushing of the face, mouth sores, heartburn and swelling of the feet and ankles.

CHRONIC HEALTH EFFECTS
- Harmful: danger of serious damage to health by prolonged exposure through inhalation.
- This material can cause serious damage if one is exposed to it for long periods. It can be assumed that it contains a substance which can produce severe defects.
- Limited evidence suggests that repeated or long-term occupational exposure may produce cumulative health effects involving organs or biochemical systems.
- Vinca alkaloids are toxic to the nervous system. There may be general unwellness, headache, depression, hallucinations, "pins and needles", muscle damage, tendon reflex loss, neural inflammation of the extremities, constipation, and obstructed small bowel.
Topoisomerase inhibitors represent a subgroup of plant alkaloids, which also encompasses the vinca alkaloids such as vincristine and vinblastine, taxanes and podophyllotoxin derivatives. Topoisomerase inhibitors act by preventing the unpackaging of DNA that must occur prior to transcription and replication. The earliest drugs in this class were inhibitors of topoisomerase II, however topoisomerase I inhibitors such as topotecan started entering the market in the mid-1990’s. DNA topoisomerase II inhibitors are among the most efficacious drugs for the treatment of cancer. Despite their widespread use, the use of topoisomerase II inhibitors is limited by severe adverse effects to normal tissues, including cardiotoxicity.

In addition to problems associated with toxicity, sensitivity of cancer cells to topoisomerase II targeting agents is also, like many other cancer therapeutics susceptible to resistance. The efficacy of this class is thought to depend on the expression of the topoisomerase llalpha isoform, and drug resistance is often associated with loss or mutation of this isoform.

**Section 3 - COMPOSITION / INFORMATION ON INGREDIENTS**

<table>
<thead>
<tr>
<th>NAME</th>
<th>CAS RN</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>vinpocetine</td>
<td>42971-09-5</td>
<td>&gt;98</td>
</tr>
</tbody>
</table>

**Section 4 - FIRST AID MEASURES**

**SWALLOWED**
- IF SWALLOWED, REFER FOR MEDICAL ATTENTION, WHERE POSSIBLE, WITHOUT DELAY. · Where Medical attention is not immediately available or where the patient is more than 15 minutes from a hospital or unless instructed otherwise:

**EYE**
- If this product comes in contact with the eyes: · Wash out immediately with fresh running water. · Ensure complete irrigation of the eye by keeping eyelids apart and away from eye and moving the eyelids by occasionally lifting the upper and lower lids.

**SKIN**
- If skin or hair contact occurs: · Flush skin and hair with running water (and soap if available). · Seek medical attention in event of irritation.

**INHALED**
- If fumes or combustion products are inhaled remove from contaminated area. · Lay patient down. Keep warm and rested.

**NOTES TO PHYSICIAN**
- for poisons (where specific treatment regime is absent):

  **BASIC TREATMENT**

  · Establish a patent airway with suction where necessary.
  · Watch for signs of respiratory insufficiency and assist ventilation as necessary.

**Section 5 - FIRE FIGHTING MEASURES**

<table>
<thead>
<tr>
<th>Vapour Pressure (mmHG):</th>
<th>Negligible</th>
</tr>
</thead>
<tbody>
<tr>
<td>Upper Explosive Limit (%):</td>
<td>Not Available</td>
</tr>
<tr>
<td>Specific Gravity (water=1):</td>
<td>Not Available</td>
</tr>
<tr>
<td>Lower Explosive Limit (%):</td>
<td>Not Available</td>
</tr>
</tbody>
</table>

**EXTINGUISHING MEDIA**
- Foam.
- Dry chemical powder.

**FIRE FIGHTING**
- Alert Emergency Responders and tell them location and nature of hazard.
- Wear breathing apparatus plus protective gloves.

**GENERAL FIRE HAZARDS/HAZARDOUS COMBUSTIBLE PRODUCTS**
- Combustible solid which burns but propagates flame with difficulty.
- Avoid generating dust, particularly clouds of dust in a confined or unventilated space as dusts may form an explosive mixture with air, and any source of ignition, i.e. flame or spark, will cause fire or explosion. Dust clouds generated by the fine grinding of the solid are a particular hazard; accumulations of fine dust may burn rapidly and fiercely if ignited.
- Combustion products include: carbon monoxide (CO), carbon dioxide (CO2), nitrogen oxides (NOx), other pyrolysis products typical of burning organic material.
- May emit poisonous fumes.

**FIRE INCOMPATIBILITY**
- Avoid contamination with oxidizing agents i.e. nitrates, oxidizing acids, chlorine bleaches, pool chlorine etc. as ignition may result.

**PERSONAL PROTECTION**
- Glasses:
- Chemical goggles.
- Gloves:
- Respirator:
- Particulate
Section 6 - ACCIDENTAL RELEASE MEASURES

MINOR SPILLS
· Clean up waste regularly and abnormal spills immediately.
· Avoid breathing dust and contact with skin and eyes.
· Wear protective clothing, gloves, safety glasses and dust respirator.
· Vacuum up or sweep up. NOTE: Vacuum cleaner must be fitted with an exhaust micro filter (HEPA type) (consider explosion-proof machines designed to be grounded during storage and use).
· Dampen with water to prevent dusting before sweeping.
· Place in suitable containers for disposal.

MAJOR SPILLS
· Moderate hazard.
· CAUTION: Advise personnel in area.
· Alert Emergency Responders and tell them location and nature of hazard.

Section 7 - HANDLING AND STORAGE

PROCEDURE FOR HANDLING
· Avoid all personal contact, including inhalation.
· Wear protective clothing when risk of exposure occurs.
· Empty containers may contain residual dust which has the potential to accumulate following settling. Such dusts may explode in the presence of an appropriate ignition source.
· Do NOT cut, drill, grind or weld such containers.
· In addition ensure such activity is not performed near full, partially empty or empty containers without appropriate workplace safety authorisation or permit.

RECOMMENDED STORAGE METHODS
· Glass container.
· Polyethylene or polypropylene container.
· Check all containers are clearly labelled and free from leaks.

STORAGE REQUIREMENTS
· Store in original containers.
· Keep containers securely sealed.

Section 8 - EXPOSURE CONTROLS / PERSONAL PROTECTION

EXPOSURE CONTROLS
The following materials had no OELs on our records
· vinpocetine: CAS:42971-09-5

PERSONAL PROTECTION

RESPIRATOR
Particulate
Consult your EHS staff for recommendations

EYE
· When handling very small quantities of the material eye protection may not be required.
· Face shield. Full face shield may be required for supplementary but never for primary protection of eyes.
· Chemical goggles.
· Contact lenses may pose a special hazard; soft contact lenses may absorb and concentrate irritants. A written policy document, describing the wearing of lens or restrictions on use, should be created for each workplace or task. This should include a review of lens absorption and adsorption for the class of chemicals in use and an account of injury experience. Medical and first-aid personnel should be trained in their removal and suitable equipment should be readily available. In the event of chemical exposure, begin eye irrigation immediately and remove contact lens as soon as practicable. Lens should be removed at the first signs of eye redness or irritation - lens should be removed in a clean environment only after workers have washed hands thoroughly. [CDC NIOSH Current Intelligence Bulletin 59].

HANDS/FEET
· Suitability and durability of glove type is dependent on usage. Important factors in the selection of gloves include: such as:
· frequency and duration of contact.
· chemical resistance of glove material,
glove thickness and dexterity

Select gloves tested to a relevant standard (e.g. Europe EN 374, US F739).
When prolonged or frequently repeated contact may occur, a glove with a protection class of 5 or higher (breakthrough time greater than 240 minutes according to EN 374) is recommended.
When only brief contact is expected, a glove with a protection class of 3 or higher (breakthrough time greater than 60 minutes according to EN 374) is recommended.
Contaminated gloves should be replaced.
Gloves must only be worn on clean hands. After using gloves, hands should be washed and dried thoroughly. Application of a non-perfumed moisturiser is recommended.

Rubber gloves (nitrile or low-protein, powder-free latex). Employees allergic to latex gloves should use nitrile gloves in preference.
Double gloving should be considered.
PVC gloves.
Protective shoe covers.
Head covering.

Experience indicates that the following polymers are suitable as glove materials for protection against undissolved, dry solids, where abrasive particles are not present.
- polychloroprene
- nitrile rubber
- butyl rubber
- fluoroelastomer
- polyvinyl chloride

Gloves should be examined for wear and/or degradation constantly.

OTHER
- For quantities up to 500 grams a laboratory coat may be suitable.
- For quantities up to 1 kilogram a disposable laboratory coat or coverall of low permeability is recommended. Coveralls should be buttoned at collar and cuffs.
- For quantities over 1 kilogram and manufacturing operations, wear disposable coverall of low permeability and disposable shoe covers.
- For manufacturing operations, air-supplied full body suits may be required for the provision of advanced respiratory protection.
- Eye wash unit.
- For Emergencies: Vinyl suit.

ENGINEERING CONTROLS
- Enclosed local exhaust ventilation is required at points of dust, fume or vapor generation.
- HEPA terminated local exhaust ventilation should be considered at point of generation of dust, fumes or vapors.

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

PHYSICAL PROPERTIES

<table>
<thead>
<tr>
<th>Property</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>State</td>
<td>Divided Solid</td>
</tr>
<tr>
<td>Melting Range (°F)</td>
<td>296.8-307.4</td>
</tr>
<tr>
<td>Boiling Range (°F)</td>
<td>Not Applicable</td>
</tr>
<tr>
<td>Flash Point (°F)</td>
<td>Not Available</td>
</tr>
<tr>
<td>Decomposition Temp (°F)</td>
<td>Not Available</td>
</tr>
<tr>
<td>Autoignition Temp (°F)</td>
<td>Not Available</td>
</tr>
<tr>
<td>Upper Explosive Limit (%)</td>
<td>Not Available</td>
</tr>
<tr>
<td>Lower Explosive Limit (%)</td>
<td>Not Available</td>
</tr>
<tr>
<td>Volatile Component (%vol)</td>
<td>Negligible</td>
</tr>
<tr>
<td>Molecular Weight</td>
<td>350.45</td>
</tr>
<tr>
<td>Viscosity</td>
<td>Not Applicable</td>
</tr>
<tr>
<td>Solubility in water (g/L)</td>
<td>Partly Miscible</td>
</tr>
<tr>
<td>pH (1% solution)</td>
<td>Not Applicable</td>
</tr>
<tr>
<td>pH (as supplied)</td>
<td>Not Applicable</td>
</tr>
<tr>
<td>Vapour Pressure (mmHG)</td>
<td>Negligible</td>
</tr>
<tr>
<td>Specific Gravity (water=1)</td>
<td>Not Available</td>
</tr>
<tr>
<td>Relative Vapor Density (air=1)</td>
<td>Not Applicable</td>
</tr>
<tr>
<td>Evaporation Rate</td>
<td>Not Applicable</td>
</tr>
</tbody>
</table>

APPEARANCE
White solid; does not mix well with water; Soluble in DMSO (5 mg/ml)

Section 10 - CHEMICAL STABILITY

CONDITIONS CONTRIBUTING TO INSTABILITY
- Presence of incompatible materials.
- Product is considered stable.

STORAGE INCOMPATIBILITY
- Avoid reaction with oxidizing agents.

For incompatible materials - refer to Section 7 - Handling and Storage.

Section 11 - TOXICOLOGICAL INFORMATION
VINPOCETINE

TOXICITY AND IRRITATION

- unless otherwise specified data extracted from RTECS - Register of Toxic Effects of Chemical Substances.

<table>
<thead>
<tr>
<th>TOXICITY</th>
<th>IRRITATION</th>
</tr>
</thead>
<tbody>
<tr>
<td>Intraperitoneal (Rat) LD50: 119 mg/kg</td>
<td></td>
</tr>
<tr>
<td>Intravenous (Rat) LD50: 32 mg/kg</td>
<td></td>
</tr>
<tr>
<td>Oral (Mouse) LD50: 534 mg/kg</td>
<td></td>
</tr>
<tr>
<td>Intraperitoneal (Mouse) LD50: 117 mg/kg</td>
<td></td>
</tr>
<tr>
<td>Intravenous (Mouse) LD50: 45 mg/kg</td>
<td></td>
</tr>
<tr>
<td>Intraperitoneal (Mouse) TDLo: 10 mg/kg</td>
<td></td>
</tr>
<tr>
<td>Intraperitoneal (Cat) TDLo: 10 mg/kg</td>
<td></td>
</tr>
<tr>
<td>Intravenous (Rat) TDLo: 10 mg/kg</td>
<td></td>
</tr>
<tr>
<td>Oral (Rat) LD50: 503 mg/kg</td>
<td></td>
</tr>
</tbody>
</table>

Side effects of vinpocetine may include indigestion, nausea, dizziness, anxiety, facial flushing, insomnia, headache, drowsiness and dry mouth. Vinpocetine may also cause a temporary drop in blood pressure. In clinical trials adverse effects have been reported infrequently, but the trials were not long-term. The safety of vinpocetine in pregnant women has not been evaluated.

Vinpocetine has been implicated in one case to induce agranulocytosis, a condition in which granulocytes, are markedly decreased. Some people have anecdotally noted that their continued use of vinpocetine reduces immune function.

Commission E warned that vinpocetine reduced immune function and could cause apoptosis in the long term.

Other alkaloids extracted from the periwinkle family, including Vincristine and Vinblastine are powerful chemotherapeutic agents which impair formation of microtubules and thus growth of related cancers, intestinal epithelium and bone marrow.

---

Section 12 - ECOLOGICAL INFORMATION

No data

Section 13 - DISPOSAL CONSIDERATIONS

Disposal Instructions

All waste must be handled in accordance with local, state and federal regulations.

- Puncture containers to prevent re-use and bury at an authorized landfill.

Legislation addressing waste disposal requirements may differ by country, state and/or territory. Each user must refer to laws operating in their area. In some areas, certain wastes must be tracked.

A Hierarchy of Controls seems to be common - the user should investigate:

- Reduction
- Reuse
- Recycling
- Disposal (if all else fails)

This material may be recycled if unused, or if it has not been contaminated so as to make it unsuitable for its intended use. Shelf life considerations should also be applied in making decisions of this type. Note that properties of a material may change in use, and recycling or reuse may not always be appropriate.

DO NOT allow wash water from cleaning equipment to enter drains. Collect all wash water for treatment before disposal.

- Recycle wherever possible.
- Consult manufacturer for recycling options or consult Waste Management Authority for disposal if no suitable treatment or disposal facility can be identified.

Section 14 - TRANSPORTATION INFORMATION

NOT REGULATED FOR TRANSPORT OF DANGEROUS GOODS: DOT, IATA, IMDG

Section 15 - REGULATORY INFORMATION

REGULATIONS

No data for vinpocetine (CAS: , 42971-09-5)
LIMITED EVIDENCE

- Inhalation may produce health damage*.
- Cumulative effects may result following exposure*.
* (limited evidence).

Reasonable care has been taken in the preparation of this information, but the author makes no warranty of merchantability or any other warranty, expressed or implied, with respect to this information. The author makes no representations and assumes no liability for any direct, incidental or consequential damages resulting from its use. For additional technical information please call our toxicology department on +800 CHEMCALL.

Classification of the preparation and its individual components has drawn on official and authoritative sources as well as independent review by the Chemwatch Classification committee using available literature references. A list of reference resources used to assist the committee may be found at: www.chemwatch.net/references.

The (M)SDS is a Hazard Communication tool and should be used to assist in the Risk Assessment. Many factors determine whether the reported Hazards are Risks in the workplace or other settings. Risks may be determined by reference to Exposures Scenarios. Scale of use, frequency of use and current or available engineering controls must be considered.

This document is copyright. Apart from any fair dealing for the purposes of private study, research, review or criticism, as permitted under the Copyright Act, no part may be reproduced by any process without written permission from CHEMWATCH. TEL (+61 3) 9572 4700.

Issue Date: Apr-16-2010
Print Date: Oct-20-2010